News & Publications

  • News

    October 6, 2020

    A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics

    Press release

  • Publication

    October 2, 2020

    Engineered T Cells Directed at Tumors With Defined Allelic Loss

    Molecular Immunology

  • Presentation

    October 1, 2020

    Engineered T Cells Directed at Tumors With Defined Allelic Loss

    3rd Cell Therapies and Immunotherapy Conference

  • Poster

    August 31,  2020

    A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics

    The Essential Protein Engineering & Cell Therapy Summit Virtual

  • Publication

    August 5, 2020

    Structure-function Relationships of Chimeric Antigen Receptors in Acute T Cell Responses to Antigen

    Molecular Immunology

  • Publication

    November 21, 2019

    Single Variable Domains from the T Cell Receptor β Chain Function as Mono-and Bifunctional CARs and TCRs

    Scientific Reports

  • News

    November 5, 2019

Contact

30301 Agoura Road #210, Agoura Hills, CA, 91301

info@a2bio.com

© 2019 A2 Biotherapeutics, Inc.